Patents by Inventor Stephen A. Chappell

Stephen A. Chappell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7432346
    Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: October 7, 2008
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
  • Publication number: 20070270580
    Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.
    Type: Application
    Filed: November 29, 2006
    Publication date: November 22, 2007
    Inventors: Vincent Mauro, Gerald Edelman, Stephen Chappell, Frederick Jones, Geoffrey Owens, Robyn Meech
  • Patent number: 7183395
    Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating the oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: February 27, 2007
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech
  • Patent number: 7124376
    Abstract: A pre-designed system-on-chip architecture and method includes several standard library devices, HDL source code, simulation environment and regression, synthesis scripts, software header files, software libraries, ASIC verification test suites, and makefiles. The standard library devices comprise an integrated CPU, a shared memory controller, a peripheral controller, system peripherals, a DMA controller, embedded memory, and general system control. CPU bridges are used to accommodate a variety of processor types and to insulate users from the complexities of interfacing to different kinds of processors. Such CPU bridges further allow the latest processors to be rapidly integrated into existing integration platforms and designs.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: October 17, 2006
    Assignee: Palmchip Corporation
    Inventors: S. Jauher A. Zaidi, Michael Ou, Lyle E. Adams, Stephen Chappell, Savitha Gandikota, Jon Udell, Brian Gutcher, Jef Munsil
  • Patent number: 7053186
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STREPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: May 30, 2006
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 6887975
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: May 3, 2005
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 6833438
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: December 21, 2004
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20040219591
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAP's are described and characterized herein. The human STEAP's exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: May 28, 2004
    Publication date: November 4, 2004
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20040219162
    Abstract: Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Application
    Filed: May 28, 2004
    Publication date: November 4, 2004
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20040072196
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: April 4, 2003
    Publication date: April 15, 2004
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20040043468
    Abstract: Synthetic and isolated translational regulatory elements, including oligonucleotides that have translational enhancing activity, internal ribosome entry site (IRES) activity, or translational inhibitory activity, and multimers of such translational regulatory elements are provided. In addition, compositions that include such translational regulatory elements are provided, as are methods of using the translational regulatory elements.
    Type: Application
    Filed: November 27, 2002
    Publication date: March 4, 2004
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Geoffrey Owens, Jason K. Pinkstaff, Leslie Krushel, Wei Zhou
  • Publication number: 20040005564
    Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating the oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.
    Type: Application
    Filed: December 9, 2002
    Publication date: January 8, 2004
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech
  • Patent number: 6652859
    Abstract: Novel testis-specific genes and encoded proteins (PTANs) are described. PTANs are over-expressed in prostate cancer. The nucleotide and amino acid sequences of three distinct PTAN isoforms, designated PTAN-1, PTAN-2 and PTAN-3 are provided. The PTANs show no homology to any known gene. The testis-specific expression profile of PTAN in normal adult tissues, combined with the over-expression observed in prostate tumor xenografts, suggests that PTAN may be aberrancy over-expressed in at least some prostate cancers, and thus may be a useful diagnostic and/or therapeutic target for prostate cancers.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: November 25, 2003
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Stephen Chappell Mitchell
  • Publication number: 20030211520
    Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
    Type: Application
    Filed: December 30, 2002
    Publication date: November 13, 2003
    Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
  • Publication number: 20030055217
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds In a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: December 6, 2001
    Publication date: March 20, 2003
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20030045682
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: December 6, 2001
    Publication date: March 6, 2003
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 6509458
    Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: January 21, 2003
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
  • Publication number: 20020038401
    Abstract: A pre-designed system-on-chip architecture and method includes several standard library devices, HDL source code, simulation environment and regression, synthesis scripts, software header files, software libraries, ASIC verification test suites, and makefiles. The standard library devices comprise an integrated CPU, a shared memory controller, a peripheral controller, system peripherals, a DMA controller, embedded memory, and general system control. CPU bridges are used to accommodate a variety of processor types and to insulate users from the complexities of interfacing to different kinds of processors. Such CPU bridges further allow the latest processors to be rapidly integrated into existing integration platforms and designs.
    Type: Application
    Filed: September 17, 2001
    Publication date: March 28, 2002
    Inventors: S. Jauher A. Zaidi, Michael Ou, Lyle E. Adams, Stephen Chappell, Savitha Gandikota, Jon Udell, Brian Gutcher, Jef Munsil
  • Patent number: 6329503
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: December 11, 2001
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell